<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03663049</url>
  </required_header>
  <id_info>
    <org_study_id>210890</org_study_id>
    <nct_id>NCT03663049</nct_id>
  </id_info>
  <brief_title>The Impact of Statin Holiday in Dialysis Patients Over 70 Years Old on Mental Function, Physical Function and Frailty</brief_title>
  <official_title>Trial of Statin Holiday in Patients Receiving Maintenance Dialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Loyola University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Loyola University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients who are on chronic dialysis and 70 and older are frequently on multiple medications
      including statins. However, the benefit of statins in dialysis patient population is
      uncertain. Several randomized trials showed no benefit of statins on mortality in dialysis
      patient population. Guidelines recommend not starting statins in patients on dialysis who are
      not already taking them. However, there are no guidelines on what to do in patients who are
      already taking statins. The investigators are doing a short pilot study to discontinue statin
      in our dialysis patient population and evaluating the effects on discontinuation of statins
      on quality of life, cognition, as physical strength.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dialysis patients who are 70 years and older suffer from cognitive dysfunction, physical
      impairment, and frailty. Polypharmacy in this subgroup of patients is prevalent and can lead
      to drug toxicities and increased side effects which can contribute to adverse outcomes such
      as worsening cognitive decline and increased frailty. One frequent component of polypharmacy
      in dialysis patient population is the use of statins. The use of statins, however, has not
      been proven to be beneficial in this patient population. While statin medications have been
      shown to reduce atherosclerotic cardiovascular disease in adults without dialysis dependent
      chronic kidney disease (CKD), the benefit of statin use in chronic dialysis patients has not
      been proven. A Cochrane meta-analysis published in 2013 included 25 trials of statin
      medications in patients receiving maintenance dialysis (total of 8289 patients) and found no
      benefit of statin medications for preventing atherosclerotic cardiovascular disease events or
      mortality. The meta-analysis did note that evidence for side effects for statins was
      incomplete and potential harms from statin medications remain uncertain in this population.
      Furthermore, statins have recently come under scrutiny by the FDA with regards to their
      safety due to associations with memory loss and weakness.

      Previous clinical trials of statins only assessed the known adverse effects of statins such
      as abnormal liver function tests and acute kidney injury, adverse effects that occur rarely
      (&lt; 1%). Trials did not assess other side effects such as cognitive decline or muscle weakness
      that may be more common in older patients with kidney failure. The aim of this pilot study is
      to examine the potential side effects of statin medication use in older patients receiving
      dialysis by conducting a randomized pilot trial of a statin holiday (3 months of
      discontinuation) vs. no holiday and measuring changes in cognitive function, muscle strength,
      quality of life and frailty. The investigators hypothesize that measures of cognitive
      function, grip strength, quality of life and overall frailty will improve after 6 weeks of
      discontinuation of statins. After obtaining informed consent, patients will complete
      assessments of quality of life (SF-20), cognition, muscle strength and frailty at baseline
      and again at 6 and 12 weeks after statin holiday (intervention group) vs. no statin holiday
      (control group). All patients will resume statin medications after the 3 month trial. The
      overall goal is to determine whether changes in cognition, strength, frailty or quality of
      life can be measured using standard instruments. If changes can be detected, pilot data from
      this study will be used to design a larger trial.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 17, 2018</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Two arms in the study. Patients will be randomized to either continue medication in the statin group or discontinue.</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in quality of life</measure>
    <time_frame>Change in quality of life over 12 weeks</time_frame>
    <description>Change in quality of life will be measured by the Short Form Survey 20 (SF-20). The survey assesses quality of life via 20 questions across 6 domains: physical functioning (6 questions), role functioning (2 questions), social functioning (1 question), mental health (5 questions), health perceptions (5 questions), and pain (1 question). Scores across each of these domains are reported on a 0% to 100% scale, with 0% representing the worst possible score in that domain and 100% the best possible score.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in handgrip strength</measure>
    <time_frame>Change in handgrip strength over 12 weeks</time_frame>
    <description>Handgrip strength will be measured at baseline and again at 6 and 12 weeks</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in cognition</measure>
    <time_frame>Change in cognition over 12 weeks</time_frame>
    <description>Cognition will be measured with trail making test at baseline and again at 6 and 12 weeks</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in frailty</measure>
    <time_frame>Change in frailty at 12 weeks</time_frame>
    <description>Frailty will be measured with the Fatigue, Resistance, Aeorbic, Illnesses, and Loss of weight (FRAIL) questionnaire at baseline and again at 6 and 12 weeks. The questionnaire rates each of the five items as 0 for no and 1 for yes, with a total score of 5 possible. Scoring scale: 1-2= pre-frail; 3 or greater=frailty</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in mobility</measure>
    <time_frame>Change in mobility at 12 weeks</time_frame>
    <description>Fall risk will be measured with the Get up and go test at baseline and again at 6 and 12 weeks. Time interpretation scale: 10 seconds or less=normal; 20 seconds or less= good mobility; 20 seconds or more = mobility problems, need for a mobility aid</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>ESRD</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Usual care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>These patients will continue as statins as usual.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Discontinue statin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to this group will stop using the statins they are currently prescribed and will not use their statin medication for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>discontinue statin</intervention_name>
    <description>Discontinue statin as prescribed for 12 weeks</description>
    <arm_group_label>Discontinue statin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 70 years and older,

          2. Receiving maintenance dialysis for at least 6 months,

          3. Must be on a statin medication,

          4. Receiving dialysis at the Loyola University Medical Center dialysis unit ,

          5. Can be on hemodialysis or peritoneal dialysis,

        Exclusion Criteria:

          1. Age less than 70 years old

          2. Any recent hospital admission (within 2 weeks)

          3. Recent dialysis start (within 6 months)

          4. Any cancer diagnosis, with exception of innocuous skin cancers and previously treated
             cancers

          5. Any recent (&lt; 1 year) solid organ transplant

          6. Active on kidney transplant wait list

          7. Recent acute coronary event (e.g. recent NSTEMI, stent, angioplasty, CABG) within 6
             months

          8. Non-English speaking

          9. Diagnosis of dementia

         10. Patients who are unable to provide informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julia Schneider</last_name>
    <role>Principal Investigator</role>
    <affiliation>Loyola University Chicago</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julia M Schneider</last_name>
    <phone>7082169000</phone>
    <email>julia.schneider@luhs.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Holly M Kramer</last_name>
    <phone>7082169000</phone>
    <email>hkramer@lumc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Loyola University M Center</last_name>
      <phone>708-216-9000</phone>
      <email>julia.schneider@luhs.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/Drugs/DrugSafety/ucm293101.htm</url>
    <description>Drug Safety and Availability - FDA Drug Safety Communication: Important safety label changes to cholesterol-lowering statin drugs [Internet].: Center for Drug Evaluation and Research [cited Mar 9, 2018]</description>
  </link>
  <reference>
    <citation>Clark DA, Khan U, Kiberd BA, Turner CC, Dixon A, Landry D, Moffatt HC, Moorhouse PA, Tennankore KK. Frailty in end-stage renal disease: comparing patient, caregiver, and clinician perspectives. BMC Nephrol. 2017 May 2;18(1):148. doi: 10.1186/s12882-017-0558-x.</citation>
    <PMID>28464924</PMID>
  </reference>
  <reference>
    <citation>McIntyre C, McQuillan R, Bell C, Battistella M. Targeted Deprescribing in an Outpatient Hemodialysis Unit: A Quality Improvement Study to Decrease Polypharmacy. Am J Kidney Dis. 2017 Nov;70(5):611-618. doi: 10.1053/j.ajkd.2017.02.374. Epub 2017 Apr 14.</citation>
    <PMID>28416321</PMID>
  </reference>
  <reference>
    <citation>St Peter WL. Management of Polypharmacy in Dialysis Patients. Semin Dial. 2015 Jul-Aug;28(4):427-32. doi: 10.1111/sdi.12377. Epub 2015 Apr 9.</citation>
    <PMID>25864928</PMID>
  </reference>
  <reference>
    <citation>Fellström BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Grönhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Süleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wüthrich RP, Gottlow M, Johnsson E, Zannad F; AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009 Apr 2;360(14):1395-407. doi: 10.1056/NEJMoa0810177. Epub 2009 Mar 30. Erratum in: N Engl J Med. 2010 Apr 15;362(15):1450.</citation>
    <PMID>19332456</PMID>
  </reference>
  <reference>
    <citation>Holdaas H, Holme I, Schmieder RE, Jardine AG, Zannad F, Norby GE, Fellström BC; AURORA study group. Rosuvastatin in diabetic hemodialysis patients. J Am Soc Nephrol. 2011 Jul;22(7):1335-41. doi: 10.1681/ASN.2010090987. Epub 2011 May 12.</citation>
    <PMID>21566054</PMID>
  </reference>
  <reference>
    <citation>Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, Krairittichai U, Ophascharoensuk V, Fellström B, Holdaas H, Tesar V, Wiecek A, Grobbee D, de Zeeuw D, Grönhagen-Riska C, Dasgupta T, Lewis D, Herrington W, Mafham M, Majoni W, Wallendszus K, Grimm R, Pedersen T, Tobert J, Armitage J, Baxter A, Bray C, Chen Y, Chen Z, Hill M, Knott C, Parish S, Simpson D, Sleight P, Young A, Collins R; SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011 Jun 25;377(9784):2181-92. doi: 10.1016/S0140-6736(11)60739-3. Epub 2011 Jun 12.</citation>
    <PMID>21663949</PMID>
  </reference>
  <reference>
    <citation>Olyaei A, Steffl JL, MacLaughlan J, Trabolsi M, Quadri SP, Abbasi I, Lerma E. HMG-CoA reductase inhibitors in chronic kidney disease. Am J Cardiovasc Drugs. 2013 Dec;13(6):385-98. doi: 10.1007/s40256-013-0041-4. Review.</citation>
    <PMID>23975627</PMID>
  </reference>
  <reference>
    <citation>Wanner C, Tonelli M; Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int. 2014 Jun;85(6):1303-9. doi: 10.1038/ki.2014.31. Epub 2014 Feb 19. Review.</citation>
    <PMID>24552851</PMID>
  </reference>
  <reference>
    <citation>Manley HJ, McClaran ML, Overbay DK, Wright MA, Reid GM, Bender WL, Neufeld TK, Hebbar S, Muther RS. Factors associated with medication-related problems in ambulatory hemodialysis patients. Am J Kidney Dis. 2003 Feb;41(2):386-93.</citation>
    <PMID>12552501</PMID>
  </reference>
  <reference>
    <citation>Talar Markossian, Holly Kramer, Nicholas Burge, et a. Utilization of statins in U.S. Veterans with dialysis-dependent chronic kidney disease. Health Sciences Research. 2018 Under review</citation>
  </reference>
  <reference>
    <citation>Kurella Tamura M, Larive B, Unruh ML, Stokes JB, Nissenson A, Mehta RL, Chertow GM; Frequent Hemodialysis Network Trial Group. Prevalence and correlates of cognitive impairment in hemodialysis patients: the Frequent Hemodialysis Network trials. Clin J Am Soc Nephrol. 2010 Aug;5(8):1429-38. doi: 10.2215/CJN.01090210. Epub 2010 Jun 24.</citation>
    <PMID>20576825</PMID>
  </reference>
  <reference>
    <citation>Johansen KL, Chertow GM, Jin C, Kutner NG. Significance of frailty among dialysis patients. J Am Soc Nephrol. 2007 Nov;18(11):2960-7. Epub 2007 Oct 17.</citation>
    <PMID>17942958</PMID>
  </reference>
  <reference>
    <citation>Herzog CA, Asinger RW, Berger AK, Charytan DM, Díez J, Hart RG, Eckardt KU, Kasiske BL, McCullough PA, Passman RS, DeLoach SS, Pun PH, Ritz E. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2011 Sep;80(6):572-86. doi: 10.1038/ki.2011.223. Epub 2011 Jul 13.</citation>
    <PMID>21750584</PMID>
  </reference>
  <reference>
    <citation>Isoyama N, Qureshi AR, Avesani CM, Lindholm B, Bàràny P, Heimbürger O, Cederholm T, Stenvinkel P, Carrero JJ. Comparative associations of muscle mass and muscle strength with mortality in dialysis patients. Clin J Am Soc Nephrol. 2014 Oct 7;9(10):1720-8. doi: 10.2215/CJN.10261013. Epub 2014 Jul 29.</citation>
    <PMID>25074839</PMID>
  </reference>
  <reference>
    <citation>Dong J, Pi HC, Xiong ZY, Liao JL, Hao L, Liu GL, Ren YP, Wang Q, Duan LP, Zheng ZX. Depression and Cognitive Impairment in Peritoneal Dialysis: A Multicenter Cross-sectional Study. Am J Kidney Dis. 2016 Jan;67(1):111-8. doi: 10.1053/j.ajkd.2015.06.025. Epub 2015 Aug 6.</citation>
    <PMID>26255306</PMID>
  </reference>
  <reference>
    <citation>Fazekas G, Fazekas F, Schmidt R, Kapeller P, Offenbacher H, Krejs GJ. Brain MRI findings and cognitive impairment in patients undergoing chronic hemodialysis treatment. J Neurol Sci. 1995 Dec;134(1-2):83-8.</citation>
    <PMID>8747848</PMID>
  </reference>
  <reference>
    <citation>Sehgal AR, Grey SF, DeOreo PB, Whitehouse PJ. Prevalence, recognition, and implications of mental impairment among hemodialysis patients. Am J Kidney Dis. 1997 Jul;30(1):41-9.</citation>
    <PMID>9214400</PMID>
  </reference>
  <reference>
    <citation>Lopes AA, Lantz B, Morgenstern H, Wang M, Bieber BA, Gillespie BW, Li Y, Painter P, Jacobson SH, Rayner HC, Mapes DL, Vanholder RC, Hasegawa T, Robinson BM, Pisoni RL. Associations of self-reported physical activity types and levels with quality of life, depression symptoms, and mortality in hemodialysis patients: the DOPPS. Clin J Am Soc Nephrol. 2014 Oct 7;9(10):1702-12. doi: 10.2215/CJN.12371213. Epub 2014 Oct 2.</citation>
    <PMID>25278548</PMID>
  </reference>
  <reference>
    <citation>Topolski TD, LoGerfo J, Patrick DL, Williams B, Walwick J, Patrick MB. The Rapid Assessment of Physical Activity (RAPA) among older adults. Prev Chronic Dis. 2006 Oct;3(4):A118. Epub 2006 Sep 15. Review.</citation>
    <PMID>16978493</PMID>
  </reference>
  <reference>
    <citation>Painter P, Marcus RL. Assessing physical function and physical activity in patients with CKD. Clin J Am Soc Nephrol. 2013 May;8(5):861-72. doi: 10.2215/CJN.06590712. Epub 2012 Dec 6. Review.</citation>
    <PMID>23220421</PMID>
  </reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>September 6, 2018</study_first_submitted>
  <study_first_submitted_qc>September 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2018</study_first_posted>
  <last_update_submitted>April 19, 2019</last_update_submitted>
  <last_update_submitted_qc>April 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Loyola University</investigator_affiliation>
    <investigator_full_name>Julia Schneider</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

